Of the cancer-associated biomarkers we have measured, the National Cancer Institute has approved only four for routine clinical use in the context of breast cancer: mutations in EGFR, HER2/neu gene overexpression, as well as uPA and PAI-1 [54]. This evidence concerns the gene EGFR and breast cancer.